Results 71 to 80 of about 5,430 (178)

Injecting Drug Use History and Younger Age Worsen Adherence to Scheduled Hospital Visits in Glecaprevir and Pibrentasvir Therapy for Chronic Hepatitis C

International Journal of Hepatology, Volume 2026, Issue 1, 2026.
Aim The use of direct‐acting antivirals (DAAs) against the Hepatitis C virus (HCV) has rapidly expanded since their introduction. However, some patients with HCV infection may still not receive appropriate medical care. This study analyzed the characteristics and adherence of the population receiving therapy with two later‐generation DAAs, glecaprevir (
Seiichi Tawara, Asuka Watanabe, Junya Yamaguchi, Mai Omi, Tetsuro Miyazaki, Haruka Taguchi, Ryosuke Kiyota, Takuo Yamai, Shoichiro Kawai, Takuya Inoue, Takayuki Yakushijin, Dirk Uhlmann   +11 more
wiley   +1 more source

Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience

, 2018
Amro M Hassan,1 Heba A Osman,2 Hasan S Mahmoud,2 Mohammed H Hassan,3 Abdel-Kader A Hashim,4 Hesham H Ameen5 1Tropical Medicine Department, Faculty of Medicine, Al-Azhar University (Assiut Branch), Assiut, Egypt; 2Tropical Medicine and Gastroenterology ...
Osman HA, Ameen HH, Hassan MH, Hashim AA, Hassan AM, Mahmoud HS   +5 more
core  

Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients

, 2017
International audienceBackground & aims - We report the first real-life results of the sofosbuvir+daclatasvir combination in hepatitis C virus (HCV) genotype 1 infected patients.
Mathurin, Philippe, Fouchard-Hubert, Isabelle, V. de Ledinghen, Chazouillères, Olivier, J.P. Zarski, D’alteroche, Louis, S. Métivier, Geist, Claire, F. Zoulim, Diallo, Alpha, J.P. Bronowicki, A. Diallo, ANRS/AFEF HEPATHER study group, A. Tran, D. Thabut, D. Samuel, V. Petrov-Sanchez, I. Rosa, Fontaine, Hélène, Tran, Albert, Carrat, Fabrice, Guyader, Dominique, O. Chazouillères, Petrov-Sanchez, Ventzislava, Loustaud-Ratti, Véronique, Dorival, Céline, Riachi, Ghassan, C. Geist, L. Alric, Bourlière, Marc, P. Mathurin, F. Carrat, Ledinghen, Victor D. E., Samuel, Didier, C. Hezode, Habersetzer, François, Causse, Xavier, A. Minello, Hézode, Christophe, Bronowicki, Jean-Pierre, L. d\u27Altéroche, Gournay, Jérôme, D. Guyader, Alric, Laurent, Marcellin, Patrick, Rosa, Isabelle, D. Larrey, C. Dorival, I. Fouchard-Hubert, E. Saillard, Thabut, Dominique, X. Causse, Billaud, Eric, V. Loustaud-Ratti, Bourcier, Valérie, Zoulim, Fabien, G. Riachi, P. Marcellin, Saillard, Eric, Metivier, Sophie, Pol, Stanislas, S. Pol, Zarski, Jean-Pierre, J. Gournay, V. Bourcier, H. Fontaine, Larrey, Dominique, M. Bourlière, Minello, Anne, E. Billaud, Lucier, Sandy, S. Lucier, F. Habersetzer   +72 more
core   +1 more source

EFFICACY AND BENEFICIAL EFFECTS OF SOFOSBUVIR WITH DACLATASVIR ON LIVER FUNCTIONS OF EARLIER TREATMENT FAILURE PATIENTS INFECTED WITH GENOTYPE 3 OF HEPATITIS C VIRUS

Pakistan Armed Forces Medical Journal, 2020
Objective: To evaluate the efficacy of sofosbuvir with daclatasvir and its promising effects on liver functions especially in respect to earlier treatment failure patients to frame an appropriate regimen for them.
Sumetha Yaseen, Kulsoom Farhat, Mahwish Gul, Syeda Urooj Zaidi, Maryam Saqib, Ayman Zafar   +5 more
doaj  

Efficacy and safety of daclatasvir-containing regimens in the treatment of chronic hepatitis C patients in Damietta

Al-Azhar Assiut Medical Journal, 2020
Background Chronic hepatitis C virus infection is one of the most important health problems in Egypt. Since November 2015, generic sofosbuvir (SOF) with daclatasvir (DCV)±ribavirin (RBV) became the standard treatment in all National Committee for Control
Alaa Eldeen M Hashim, Samy Zaky, Magdy Z Alghannam, Sabry A Ibraheem, Fathiya M El-Raey, Ahmed Abdelaziz   +5 more
doaj   +1 more source

Analysis of a Mathematical Model on the Dynamics of TB–HCV Coinfection With Medication

Journal of Applied Mathematics, Volume 2026, Issue 1, 2026.
This study employs a deterministic model that describes the combined dynamics of TB and HCV aimed at determining the impact of medication in the management of TB–HCV coinfection. The analytical and numerical analyses indicate that if the TB–HCV coinfection effective reproduction number is less than unity, the absence of both TB and HCV infections ...
Kizito Mohammed, Hasifa Nampala, Pius Ariho, Theodore Simos   +3 more
wiley   +1 more source

Evaluation of the effi cacy and safety of the use of asunaprevir in combination with daclatasvir in patients with chronic hepatitis С: a prospective cohort study

Медицинский вестник Юга России, 2017
Objective: to give assessment of the effi cacy and safety of using asunaprevir in combination with daclatasvir in patients with chronic hepatitis C (HCV) with severe fi brosis and cirrhosis.
Elena B. Romanova, Yuri M. Ambalov, Dmitry V. Sizyakin, Irina Y. Khomenko, Oleg I. Khomenko, Karina R. Titiryan   +5 more
doaj   +1 more source

Boletín CIME 02 : Daclatasvir

, 2016
Publicaciones CIMEFil: Sola, Nancy. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas; Argentina.Este Boletín está estructurado con una introducción general del ingrediente farmacéutico activo daclatasvir, su aprobación en Argentina y la ...
Sola, Nancy
core  

The safety of daclatasvir for the treatment of hepatitis C

, 2015
INTRODUCTION: The direct acting antiviral daclatasvir is an NS5A replication inhibitor active against the entire range of hepatitis C virus genotypes. It is a key step in establishing the goal of an all-oral, ribavirin-free, pan-genotypic regimen against
Gordon, Stuart C, Jafri, Syed-Mohammed
core  

A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir [PDF]

, 2020
Hepatitis C virus (HCV) genotype 3 presents a high level of both baseline and acquired resistance to direct-acting antivirals (DAAs), particularly those targeting the NS5A protein.
Vilela Rodrigues, JP, Ward, J, Souza, FF, Rahal, P, Bittar, C, Pereira, LRL, Chen, S, Harris, M, Martinelli, ADLC, Fernandes Campos, GR   +9 more
core   +1 more source